TSE:IN InMed Pharmaceuticals - IN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Share Today's Range N/A50-Day RangeC$4.19▼C$4.1952-Week Range N/AVolume17,035 shsAverage Volume29,552 shsMarket CapitalizationC$33.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsInsider TradesHeadlinesSocial Media About InMed Pharmaceuticals (TSE:IN) StockInMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.Read More Receive IN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IN Stock News HeadlinesJanuary 24, 2023 | marketwatch.comGlobal Blepharitis-Pipeline Market Size Growth Rate Analysis 2023 by Market Overview, Segments, Regions, Market Share and Forecast to 2028January 4, 2023 | marketwatch.comThinking about buying stock in Geron Corp, InMed Pharmaceuticals, Kingsoft Cloud, Vivos Therapeutics, or Baozun?January 27, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.December 14, 2022 | marketwatch.comSpasticity Treatment Market Research Highlighting Global Opportunities 2023 | Growth Trends and Share Forecast to 2029December 12, 2022 | nz.finance.yahoo.comInMed Announces Appointment of Interim Chief Financial Officer and Change of AuditorNovember 23, 2022 | msn.comBiotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory UpdateNovember 17, 2022 | finance.yahoo.comInMed (INM) Gets Grant to Begin Neurodegenerative Diseases ProgramNovember 16, 2022 | msn.comWhy Target Shares Are Trading Lower By 14%? Here Are 56 Stocks Moving In Wednesday's Mid-Day SessionJanuary 27, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.November 16, 2022 | benzinga.comThinking about buying stock in Fast Radius, Camber Energy, InMed Pharmaceuticals, Taiwan Semiconductor, or Exela Technologies?November 16, 2022 | msn.comInMed stock rockets after research grant awarded for cannabinoid analogs to treat Alzheimer's, Parkinson'sNovember 12, 2022 | finanznachrichten.deInMed Pharmaceuticals Inc.: InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business UpdateNovember 12, 2022 | benzinga.comInMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business UpdateSeptember 30, 2022 | marketwatch.comInMed Pharmaceuticals Shares Rise 30% on Higher-Than-Normal VolumeSeptember 9, 2022 | nasdaq.comInMed Pharma Gains 9%August 25, 2022 | marketwatch.comInMed Pharma to Consolidate SharesAugust 25, 2022 | uk.investing.comHere's Why InMed Pharmaceuticals Shares Are Getting Hammered TodayAugust 25, 2022 | seekingalpha.comInMed Pharmaceuticals sinks 16% over consolidating 1 for 25 shares to meet listing requirementsJuly 25, 2022 | finance.yahoo.comInMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis BullosaJuly 18, 2022 | markets.businessinsider.comInMed Pharma Names Michael Woudenberg As COOJune 14, 2022 | finance.yahoo.comInMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin ConditionsJune 9, 2022 | finance.yahoo.comInMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness SectorMay 4, 2022 | finanznachrichten.deEdison Investment Research Limited: InMed Pharmaceuticals : Notable Launches of High-Value Rare CannabinoidsApril 21, 2022 | baystreet.caThis is Why Investors Are Excited About the Potential of Rare CannabinoidsMarch 17, 2022 | benzinga.comInMed Launching Additional Rare Cannabinoids In Response To DemandMarch 17, 2022 | seekingalpha.comInMed CFO steps down, interim CFO appointedMarch 17, 2022 | nasdaq.comInMed Pharma CFO Bruce Colwill To Retire - Quick FactsSee More Headlines Receive IN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolTSE:IN CUSIPN/A CIKN/A Webwww.inmedpharma.com Phone604-669-7207FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio8.48 Current Ratio2.13 Quick Ratio1.45 Sales & Book Value Annual SalesC$574,677.00 Price / Sales0.00 Cash FlowN/A Price / Cash Flow10.40 Book ValueC$0.76 per share Price / BookN/AMiscellaneous Outstanding Shares8,051,000Free FloatN/AMarket CapC$33.73 million OptionableNot Optionable BetaN/A Key ExecutivesMr. Eric A. Adams (Age 58)Pres, CEO & Director Comp: $488.44kMs. Alexandra Diane-Janet Mancini (Age 69)Sr. VP of Clinical & Regulatory Affairs Comp: $337.13kDr. Sazzad Hossain M.Sc. (Age 64)Ph.D., Co-Founder Ms. Brenda Edwards C.M.A.CPA, Interim Chief Financial OfficerMr. Michael Woudenberg P.Eng. (Age 55)Chief Operating Officer Colin ClancySr. Director of Investor RelationsMr. Jerry P. GriffinVP of Sales & MarketingDr. Eric Chih-Hsien Hsu (Age 52)Sr. VP of Preclinical R&D Dr. Shane A. Johnson Ph.D.Sr. VP & GM of BayMedicaDr. Ado MuhammadSr. Consultant of Medical AffairsMore ExecutivesKey CompetitorsMeta GrowthCVE:METAZomedica Pharmaceuticals Corp. (ZOM.V)CVE:ZOMAleafia HealthTSE:AHViridium Pacific GroupCVE:VIRMediPharm LabsTSE:LABSView All CompetitorsInsiders & InstitutionsEric Ashley AdamsBought 8,560 shares on 4/13/2022Total: C$9,167.76 ($1.07/share)View All Insider Transactions IN Stock - Frequently Asked Questions What other stocks do shareholders of InMed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other InMed Pharmaceuticals investors own include Organigram (OGI), Aurora Cannabis (ACB), Canopy Growth (WEED), Baidu (BIDU), Cara Therapeutics (CARA), Copper Mountain Mining (CMMC), Corbus Pharmaceuticals (CRBP), HEXO (HEXO), InMed Pharmaceuticals (IMLFF) and Immunomedics (IMMU). What is InMed Pharmaceuticals' stock symbol? InMed Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "IN." How do I buy shares of InMed Pharmaceuticals? Shares of IN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. How much money does InMed Pharmaceuticals make? InMed Pharmaceuticals (TSE:IN) has a market capitalization of C$0.00 and generates C$574,677.00 in revenue each year. How can I contact InMed Pharmaceuticals? The official website for the company is www.inmedpharma.com. The company can be reached via phone at 604-669-7207. This page (TSE:IN) was last updated on 1/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.